|
|
Histidinemia
National Organization for Rare Disorders, Inc.
Synonyms
- Histidase Deficiency
- Histidine Ammonia-Lyase (HAL) Deficiency
- HAL Deficiency
- HIS Deficiency
- Hyperhistidinemia
Disorder Subdivisions
General Discussion
Histidinemia is a rare hereditary metabolic disorder characterized by a deficiency of the enzyme histidase, which is necessary for the metabolism of the amino acid histidine. The concentration of histidine is elevated in the blood. Excessive amounts of histidine, imidazole pyruvic acid, and other imidazole metabolism products are excreted in the urine. The majority of individuals with histidinemia have no obvious symptoms that would indicate that a person has this disorder (asymptomatic). Histidinemia is inherited as an autosomal recessive trait. .
Symptoms
Histidinemia is considered a benign condition. For years, mental retardation and speech defects were associated with histidinemia. However, these findings are now considered coincidental and not due to the metabolic defect of histidinemia because several recent newborn screenings demonstrated that the majority of infants with histidinemia do not develop any clinical symptoms (asymptomatic).
Individuals with histidinemia have elevated levels of the amino acid histidine in the blood and excessive amounts of histidine, imidazole pyruvic acid, and other imidazole metabolism products in the urine. Most persons with histidinemia adapt to the presence of excessive histidine in the blood and do not suffer any ill effects.
According to the medical literature, infants born to mothers with histidinemia have exhibited no symptoms. .
Causes
Histidinemia is inherited as an autosomal recessive trait. Genetic diseases are determined by two genes, one received from the father and one from the mother.
Recessive genetic disorders occur when an individual inherits the same abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%.
Researchers believe that histidinemia is due to mutations of the human histidase gene (HAL) located on the long arm (q) of chromosome 12 (12q22-q24.1). Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Pairs of human chromosomes are numbered from 1 through 22, and an additional 23rd pair of sex chromosomes which include one X and one Y chromosome in males and two X chromosomes in females. Each chromosome has a short arm designated "p" and a long arm designated "q". Chromosomes are further sub-divided into many bands that are numbered. For example, "chromosome 12q22" refers to band 2 on the long arm of chromosome 22. The numbered bands specify the location of the thousands of genes that are present on each chromosome. .
Affected Populations
Histidinemia is one of the most common inborn errors of metabolism. Based upon newborn screening of more than 20 million infants in several countries, histidinemia is estimated to occur in about one in 11,500 births overall. The disorder appears to be most prevalent among people of French Canadian or Japanese descent. Based upon newborn screening reports, approximately one in 8,600 infants in Quebec and one in 9,500 infants in Japan are affected by the disorder. The abnormality begins at birth and affects males and females in equal numbers. Histidinemia is now thought to be a primarily benign disorder. .
Standard Therapies
Diagnosis In some states in the United States (e.g., New York and Massachusetts) routine screening of newborns for histidinemia was conducted through blood or urine tests. However, newborn screening for histidenemia has been discontinued. A diagnosis of histidinemia may be made based upon increased levels of histidine in the blood or urine.
Treatment Histidinemia is considered a benign, asymptomatic disorder that does not require treatment. According to the medical literature, therapy consisting of a carefully monitored histidine-restricted diet was once recommended, but is no longer called for.
Genetic counseling may also be of benefit to affected individuals and their families. Other treatment is symptomatic and supportive. .
References
McKusick VA, ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Entry No: 235800; Last Update:6/11/99.
TEXTBOOKS Buist NRM, Winter SC. Histidinemia. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:459.
Lyon G, et al., eds. Neurology of Hereditary Metabolic Diseases in Childhood. 2nd ed. New York, NY: McGraw-Hill Companies; 1996:89-91.
Scriver CR, et al., eds. The Metabolic and Molecular Basis of Inherited Disease. 7th Ed. New York, NY; McGraw-Hill Companies, Inc; 1995:1107-23.
Buyce ML., ed. Birth Defects Encyclopedia. Dover, MA: Blackwell Scientific Publications; For: The Center for Birth Defects Information Services Inc; 1990: 875.
JOURNAL ARTICLES Lam WK, et al. Histidinaemia: a benign metabolic disorder. Arch Dis Child. 74;1996:343-6.
Suchi M , et al. Molecular cloning and structural characterization of the human histidase gene (HAL). Genomics. 1995;29:98-104.
Widhalm K, Virmani K. Long-term follow-up of 58 patients with histidinemia treated with a histidine-restricted diet: no effect of therapy. Pediatrics. 1994;94:861-6.
Virmani K, Widhalm K. Histidinemia: a biochemical variant or a disease? J Am Coll Nutr. 1993;12:115-24.
Taylor RG, et al. Localization of histidase to human chromosome region 12q22-q24.1 and mouse chromosome region 10c2-d1. Cytogenet Cell Genet. 56;1991:178-81.
Taylor RG, et al. Molecular characterization of histidase cdnas, and sublocalization of the human histidase gene to 12q22-23, and the mouse gene to 10c2-d1. Am J Hum Genet. 45;1989:A164.
Lemieux B, et al. Newborn urine screening experience with over one million infants in the Quebec network of genetic medicine. J Inherit Metab Dis. 11;1988:45-55.
Dyme IZ, et al. Histidinemia. A case of resolution of myoclonic seizures after treatment with a low-histidine diet. Am J Dis Child. 1983;137:256-8.
Scriver CR, et al. Histidinaemia. Part I: reconciling retrospective and prospective findings. Journal Inherited Metab Dis. 1983;6:51-3.
Rosenmann A, et al. Histidinaemia. Part II: impact; a retrospective study. Journal Inherited Metab Dis. 1983;6:54-7.
Coulombe JT, et al. Histidinaemia. Part III: impact; a prospective study. Journal Inherited Metab Dis. 1983;6:58-61.
Snyderman SE, et al. The nutritional therapy of histidinemia. J Pediatr. 1979;95:712-5.
INTERNET: Histidinemia www.orpha.net/static/GB/histidinemia.html
Resources
CLIMB (Children Living with Inherited Metabolic Diseases)
Climb Building 176 Nantwich Road Crewe, Intl CW2 6BG United Kingdom Tel: +44 870 7700 325 Fax: +44 870 7700 327 Email: info@climb.org.uk Internet: http://www.CLIMB.org.uk
NIH/National Institute of Diabetes, Digestive & Kidney Diseases
Endocrine Diseases Metabolic Diseases Branch 2 Information Way Bethesda, MD 20892-3570 Tel: (301)654-3810 Fax: (301)496-7422 Email: NDDIC@info.niddk.nih.gov Internet: http://www.niddk.nih.gov
Genetic and Rare Diseases (GARD) Information Center
PO Box 8126 Gaithersburg, MD 20898-8126 Tel: (301)519-3194 Fax: (240)632-9164 Tel: (888)205-2311 TDD: (888)205-3223 Email: gardinfo@nih.gov Internet: http://www.genome.gov/100000409 or http://rarediseases.info.nih.gov/html/resources/info_cntr.html
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). A copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for
informational purposes only. NORD recommends that affected individuals seek the advice or counsel of
their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms
listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the
topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease
Database completely current and accurate. Please check with the agencies listed in the Resources section
for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization
for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site
www.rarediseases.org or email orphan@rarediseases.org
Last Updated: 9/17/2007
Copyright 1988, 1989, 1996, 2003, 2007
National Organization for Rare Disorders, Inc.
|
|
|
This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
|
|